Vanberra Signal

Nimbus Therapeutics

Curated by Signal

Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases

Overview

Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.

Key facts

Founded
2009

Business model

Contact

Open roles

2 roles
  • Director/Senior Director, Nonclinical Safety (Toxicology)

    Boston, MA · On-site · Volunteer

  • Executive Director, Nonclinical Safety (Pathology & Toxicology)

    Boston, MA

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Developer of emergency medical alert systems for senior care

    Life Sciences TechnologyWilliamsport, United States
  • Developer of a system for preserving the tumor microenvironment

    Life Sciences TechnologyMadison, United States
  • Developer of treatment solutions for diabetes, endocrinology and metabolic diseases

    Life Sciences TechnologyJacksonville, United States

About Nimbus Therapeutics

What does Nimbus Therapeutics do?

Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases.

Where is Nimbus Therapeutics headquartered?

Nimbus Therapeutics is headquartered in Cambridge, United States.

When was Nimbus Therapeutics founded?

Nimbus Therapeutics was founded in 2009.

Which sector is Nimbus Therapeutics in?

Nimbus Therapeutics operates in Life Sciences Technology.

Who are Nimbus Therapeutics's competitors?

Companies similar to Nimbus Therapeutics include Alert 1, Farcast Biosciences, and Cleveland Diabetes Care.

Is Nimbus Therapeutics hiring?

Yes. Nimbus Therapeutics has 2 open roles listed on Vanberra Signal.